EPRX Eupraxia Pharmaceuticals Inc.

TSX · CA · Healthcare · Biotechnology · eupraxiapharma.com

10.69CAD+3.59%Mkt Cap: 496.58M $P/E: —Today

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug de…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap496.58M USD

Enterprise Value419.67M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-28.09M USD

Revenue/Share—

Last Price10.69 CAD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees49

CountryCA

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-7.04

PEG—

EV/EBITDA-10.13

EV/Revenue—

P/S—

P/B4.74

EPS (TTM)-1.41

EPS (Forward)-1.47

52W Range

7.35058% of range13.08

52W High13.08 CAD

52W Low7.350 CAD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-47.02%

ROA-44.78%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-20.79M USD

CapEx (TTM)428.91K USD

FCF Margin—

FCF Yield-2.78%

Net Debt-96.00M USD

Net Debt/EBITDA2.32

Balance Sheet

Debt/Equity0.00

Current Ratio16.00

Quick Ratio15.71

Book Value/Sh2.18 CAD

Cash/Share2.03 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)16.33 CAD

Upside (mean)+52.8%

Target Range14.00 CAD – 18.00 CAD

14.00+52.8% to mean18.00

# Analysts3

Ownership

Shares Out.66.07M

Float55.67M

Insiders12.11%

Institutions43.34%

Short Interest

Short Ratio1.4d

Short % Float0.19%

Short % Out.0.15%

Shares Short98.78K

Short (prev mo.)67.03K

Technical

SMA 5010.21 (+4.7%)

SMA 20010.18 (+5.0%)

Beta1.49

S&P 52W Chg14.58%

Avg Vol (30d)86.94K

Avg Vol (10d)112.32K

Technical Indicators

RSI (14)45.4

MACD0.4070

MACD Signal0.5356

MACD Hist.-0.1286

BB Upper12.64 CAD

BB Middle11.38 CAD

BB Lower10.12 CAD

BB Width22.18%

ATR (14)0.7865 CAD

Vol Ratio (20d)1.88x